You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Enhertu improves progression-free survival in breast cancer trial

Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).